LopezJimenez ND, Cavenagh MM, Sainz E, Cruz-Ithier MA, Battey JF, Sullivan SL
Mounjaro and Zepbound are Lillys dual agonists that seem to surpass Novo Nordisks Ozempic and Wegovy in weight loss power
This multi-receptor mechanism distinguishes retatrutide from earlier generations of incretin-based research compounds including GLP-1 mono-agonists such as semaglutide, and dual GIP/GLP-1 agonists such as tirzepatide by introducing glucagon receptor activation as an additional metabolic axis
Those findings do not make a research peptide an approved medication for self-directed weight loss
These are not FDA approved medications
So when taking a blood thinner, you might notice increased bleeding from cuts or scrapes, more frequent or more intense nosebleeds, or heavier-than-normal periods